Cargando…
Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells
Various CD7-targeting immunotoxins have been tested for its potential in treating CD7+ malignant patients but none of those immunotoxins was approved clinically because of lacking enough efficacy and safety. Here we successfully constructed the monovalent and bivalent CD7 nanobody-based immunotoxins...
Autores principales: | Tang, Jinle, Li, Jialu, Zhu, Xuejun, Yu, Yuan, Chen, Dan, Yuan, Lei, Gu, Zhenyang, Zhang, Xingding, Qi, Lin, Gong, Zhishu, Jiang, Pengjun, Yu, Juhua, Meng, Huimin, An, Gangli, Zheng, Huyong, Yang, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085138/ https://www.ncbi.nlm.nih.gov/pubmed/27083001 http://dx.doi.org/10.18632/oncotarget.8710 |
Ejemplares similares
-
Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential
por: Yu, Yuan, et al.
Publicado: (2017) -
B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.
por: Vooijs, W. C., et al.
Publicado: (1997) -
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
por: Zou, Jianxuan, et al.
Publicado: (2015) -
Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin
por: Flavell, D J, et al.
Publicado: (2001) -
Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)